EN DE
Watch OBI Pharma for free: we tell you when fair value or trend changes.
Data-driven stock valuation

OBI Pharma (4174) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of OBI Pharma stock TWD 32.05, price TWD 55.00, that is 41.7% below the price, quality 39 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0004174008

OP OBI Pharma logo Thin data Nov 10, 2026

OBI Pharma

4174 · TWO
Very expensive, weak quality

Our calculation puts a fair price 42% below what the stock costs today.

Low debt
Revenue last quarter +20% vs. a year ago.
Fair value 32.05 TWD · Strongly overvalued
Quality 39/100
Weak Growth (revenue 5y −16.1 %/yr in TWD)
Negative free cash flow
Trails peers (2/7)
Narrow moat 12/100
Thin data
Estimate
Watch OBI Pharma for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

265.72 TWD 24.60 TWD Fair Value 32.05 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 24.60 TWD – 265.72 TWD · fair‑value band 24.04 TWD – 40.06 TWD · the 55.00 TWD price screens above the 32.05 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow OBI Pharma in your weekly email

Every Wednesday you see whether OBI Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

OBI Pharma, Inc., a clinical stage oncology company, researches and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally.

Show moreShow less

The company's pipeline products include Adagloxad simolenin, which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424, which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment of solid tumors; OBI-902 and OBI-904 that are in preclinical stage for the treatment of solid tumors; OBI-999 is a novel first-in-class Antibody Drug Conjugate (ADC) with a proprietary linker technology that provides a consistent Drug-to-Antibody ratio (DAR) for cancer treatment; and BsADC which is in discovery stage for the treatment of solid tumors.

It also engages in investing and trading; and manufacture and wholesale of western medicines, as well as research and development of biotechnology. OBI Pharma, Inc. was founded in 2002 and is headquartered in Taipei, Taiwan.

Stock analysis

OBI Pharma (4174) currently trades at 55.00 TWD, while our estimate is 32.05 TWD, 42% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 24.04 TWD (bear) to 40.06 TWD (bull), the price of 55.00 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

OBI Pharma reported revenue of 58.6M TWD in FY2025 versus 18.8M TWD in FY2021, a compound +32.9%/yr. Reported net income was −2.1B TWD in FY2025.

Key figures

Market cap 7.2B TWD (≈ $220M) Micro · EPS (TTM) −26.90 TWD · Return on equity −61.7% · Return on assets (EBIT) −42.0% (5-year average) · Operating margin −1,381% · Revenue (TTM) 52.2M TWD · Revenue growth (YoY) +19.8% · Free cash flow −2.1B TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 14% below its 52-week high and 124% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −42%, 4174 screens richer than that median.

Fair Value

Bear 24.04 TWD Fair Value 32.05 TWD Bull 40.06 TWD
Price 55.00 TWD · Downside -41.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 31
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 57
How calm the share price moves, does not count
Price momentum 81
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 61
Distance to the 52-week high, does not count
New shares 90
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−6.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.1%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,057.2% (2020) → −3,702.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

4174 screens overvalued: fair value 42% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare OBI Pharma with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside −41.7% · Below median
Profitability
Return on assets −60.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 19.8% · Above median
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.83× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)99 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 4174
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 4174
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 4174
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 4174
argenx SE ARGX $971.55 $908.40 −7% vs 4174
CSL Limited CSL A$201.68 A$181.40 −10% vs 4174
Moderna, Inc MRNA $250.83 $158.70 −37% vs 4174
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 4174
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 4174
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 4174

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

OBI Pharma: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "OBI Pharma Fair Value". https://www.fairvalue-calculator.com/stock/4174

Frequently asked questions

Is OBI Pharma (4174) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 32.05 TWD versus a price of 55.00 TWD, about 42% lower (overvalued).
What is the fair value of 4174?
Our estimate for OBI Pharma is 32.05 TWD (as of Nov 10, 2026), built from audited fundamentals. The current price: 55.00 TWD.
What is the quality score of 4174?
OBI Pharma has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for OBI Pharma (4174)?
Our calculated price target is the estimate of 32.05 TWD (as of Nov 10, 2026). Cautious scenario 24.04 TWD, optimistic scenario 40.06 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the OBI Pharma stock forecast for 2026?
Our estimate puts fair value at 32.05 TWD, about 42% lower versus a price of 55.00 TWD (overvalued). Cautious scenario 24.04 TWD, optimistic scenario 40.06 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of OBI Pharma (4174)?
OBI Pharma reported trailing-twelve-month revenue of about 52.2M TWD (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of OBI Pharma (4174)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For OBI Pharma it is 32.05 TWD per share (as of Nov 10, 2026), against a price of 55.00 TWD.
Is OBI Pharma stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 4174 trades above its calculated fair value: price 55.00 TWD, fair value 32.05 TWD, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4174?
No. The price is what the market pays today (55.00 TWD); the fair value is what the company's own numbers justify (32.05 TWD). For OBI Pharma the two are 22.95 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is OBI Pharma worth?
The market values OBI Pharma at about 7.2B TWD (market capitalisation, as of Nov 10, 2026). Per share that is 55.00 TWD; our models calculate a fair value of 32.05 TWD per share.
What do the bullish and bearish scenarios say about 4174?
Our models span a range for OBI Pharma: cautious scenario 24.04 TWD, base 32.05 TWD, optimistic 40.06 TWD per share (as of Nov 10, 2026, price 55.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of OBI Pharma (4174)?
Balance-sheet figures for OBI Pharma (as of Nov 10, 2026): return on equity −61.7%, debt of 0.02 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 4174 from its 52-week high?
OBI Pharma trades at 55.00 TWD, about 14% below its 52-week high of 63.60 TWD and 124% above the low of 24.60 TWD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 32.05 TWD is for.
Which stocks are comparable to OBI Pharma?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is OBI Pharma stock attractive at the current price?
The data as of Nov 10, 2026: price 55.00 TWD, calculated fair value 32.05 TWD (−42%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. OBI Pharma itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of OBI Pharma (4174)?
The closing price on Nov 10, 2026 was 55.00 TWD. Our estimate is 32.05 TWD, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with OBI Pharma right now?
The price sits above even our optimistic bull case (40.06 TWD). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of OBI Pharma

How large is the market capitalisation of OBI Pharma (4174)?
The market capitalisation of OBI Pharma is 7.2B TWD (≈ $220M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of OBI Pharma (4174)?
Earnings per share at OBI Pharma are −26.90 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of OBI Pharma (4174)?
The return on equity (ROE) of OBI Pharma is −61.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of OBI Pharma (4174)?
On an EBIT basis the return on assets of OBI Pharma is −42.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of OBI Pharma (4174)?
The operating margin of OBI Pharma is −1,381% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at OBI Pharma (4174)?
Revenue at OBI Pharma is growing +19.8% versus a year earlier (3y avg +132%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does OBI Pharma (4174) generate?
The free cash flow of OBI Pharma is −2.1B TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does OBI Pharma (4174) hold?
OBI Pharma holds more cash than debt, 398M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch OBI Pharma in the live analysis

One click puts OBI Pharma on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.